Novartis Revises U.S. Regulatory Strategy For Key Respiratory Drug
This article was originally published in The Pink Sheet Daily
The Swiss drug maker says it has agreed with FDA on a Phase III trial design for the combination respiratory drug QVA149 and expects to file in late 2014; plan now calls for testing a twice-daily dose in addition to once-daily.
You may also be interested in...
The lead LAMA/LABA combination for COPD will be reviewed at the Sept. 10 session of the Pulmonary-Allergy Drugs Advisory Committee.
GSK And Novartis Look To Emerging Markets Even As Growth Slowed In Q1 – Emerging Market Earnings Roundup (Part 3)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
A review of a potential association between Novartis's oral multiple sclerosis therapy Gilenya and sudden death was inconclusive, say EU regulators, but monitoring requirements are still strengthened as a precaution.